Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025)

Pulmonx (LUNG) has 7 years of Cash from Financing Activities data on file, last reported at $181000.0 in Q3 2025.

• On a quarterly basis, Cash from Financing Activities fell 60.57% year-over-year to $181000.0 in Q3 2025; TTM through Sep 2025 was $840000.0, a 36.27% decrease from a year earlier, with the FY2024 full-year figure at $1.4 million, down 93.63% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $181000.0, up from -$67000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for LUNG reached as high as $20.7 million in Q1 2023 and fell as low as -$67000.0 in Q2 2025.
• Historically, Cash from Financing Activities has averaged $1.6 million across 5 years, with a median of $181000.0 in 2025.
• Across the five-year window, Cash from Financing Activities surged 10015.38% in 2022 and plunged 204.55% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $150000.0 in 2021, then tumbled by 55.33% to $67000.0 in 2022, then slumped by 74.63% to $17000.0 in 2023, then soared by 264.71% to $62000.0 in 2024, then surged by 191.94% to $181000.0 in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $181000.0 in Q3 2025, -$67000.0 in Q2 2025, and $664000.0 in Q1 2025.